Clinipace Acquires German CRO Accovion
Clinipace Worldwide has announced the takeover of Accovion, a CRO with a head office in Frankfurt (Eschborn), Germany.
Clinipace Worldwide has announced the takeover of Accovion, a CRO with a head office in Frankfurt (Eschborn), Germany.
Accovion provides a range of clinical research services to the pharma, biotech and medical device sectors. It has operated for more than 10 years, and is active in more than 20 countries. Clinipace is seeking to broaden its operational and therapeutic expertise in Russia, Italy, Czech Republic, Romania, Poland, Spain, France and Ukraine.
Dr. Andree Beckerling, CEO of Accovion, will have day-to-day responsibility for all European offices, including existing Clinipace staff and locations. He will report to Clinipace CEO, Jeff Williams, and will join the company’s Executive Committee.
“To be competitive in today’s market, it is important to have, among other things, a strong multi-national scale, broad therapeutic expertise and a better service delivery model,” said Williams, CEO of Clinipace Worldwide. “Bringing our companies together substantially enhances our existing European footprint throughout Western, Central and Eastern Europe and enables us to offer a competitive array of global clinical development and regulatory services in these regions.”
Clinipace provides the right combination of complementary operational strengths, services and geography, according to Beckerling. Accovion’s clients gain access to Clinipace’s dCRO delivery model supported by their proprietary TEMPO eClinical platform and a comprehensive and integrated clinical operations, data management, biostatistics and regulatory consultancy with a large worldwide footprint, he added.
This is the sixth acquisition by Clinipace in the past few years, and it now has almost 1000 global staff. The combined company has managed over 3,000 clinical research studies and more than 300 regulatory and strategic development engagements, according to the announcement.
For the full press release, click here.
SOUL Trial Shows Oral Semaglutide Significantly Reduces Cardiovascular Risk in Type 2 Diabetes
April 3rd 2025Phase III SOUL trial shows daily oral semaglutide lowers the risk of major adverse cardiovascular events in patients with type 2 diabetes and atherosclerotic cardiovascular disease or chronic kidney disease, with benefits consistent with injectable semaglutide and other GLP-1 receptor agonists.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Reaching Diverse Patient Populations With Personalized Treatment Methods
January 20th 2025Daejin Abidoye, head of solid tumors, oncology development, AbbVie, discusses a number of topics around diversity in clinical research including industry’s greatest challenges in reaching diverse patient populations, personalized treatment methods, recruitment strategies, and more.
Phase III Trial Data Show Subcutaneous Pembrolizumab as Noninferior to IV Keytruda
March 31st 2025Subcutaneous administration of pembrolizumab with chemotherapy demonstrated a nearly 50% reduction in patient chair and treatment room time while maintaining efficacy and safety endpoints compared to intravenous Keytruda.
